证券代码：688091 证券简称：上海谊众 公告编号：2025-031 上海谊众药业股份有限公司及全资子公司使用部分 闲置募集资金进行现金管理的公告 注 1："年产 500 万支注射用紫杉醇聚合物胶束及配套设施建设"将由全资子公司上海联峥生物 科技有限公司投入 136,895,000.00 元用于生产综合厂房建设等土建工程，其余资金由上海谊众 负责自动化生产、检测及包装生产线建设，同时对现有能源供应、环保设施等进行改造建设等。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 上海谊众药业股份有限公司（以下简称"公司"或"上海谊众"）于 2025 年 8 月 7 日召开了第二届董事会第十一次会议，审议通过了《关于公司及全资子公司使用 部分闲置募集资金进行现金管理的议案》。同意公司及全资子公司在确保不影响募 集资金投资项目进度、不影响公司正常生产经营及确保资金安全的前提下，使用 额度不超过人民币 450,000,000.00 元的部分暂时闲置募集资金进行现金管理，用于 购买安全性高、流动性好、满足保本要求的产品（包括但不限于购 ...

证券代码：688091 证券简称：上海谊众 公告编号：2025-030 上海谊众药业股份有限公司 第二届董事会第十一次会议决议公告 2、审议通过《关于公司及全资子公司使用部分闲置募集资金进行现金管理的 议案》 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 上海谊众药业股份有限公司（以下简称"公司"）第二届董事会第十一次会议（以 下简称"会议"）于 2025 年 8 月 7 日以现场结合通讯方式召开，会议通知已于 2025 年 8 月 2 日以通讯方式送达全体董事。会议应出席董事 6 人，实际出席董事 6 人， 本次会议由公司董事长周劲松召集和主持。会议的召集和召开程序符合有关法律 法规的规定，会议决议合法、有效。 二、董事会会议审议情况 本次会议经全体董事表决，形成决议如下： 1、审议通过《关于上海谊众药业股份有限公司 2025 年半年度报告及报告摘要 的议案》 董事会认为：公司 2025 年半年度报告的编制和审议程序符合相关法律法规及 《公司章程》等内部规章制度的规定；公司 2025 年半年度报 ...

上海谊众药业股份有限公司2025 年半年度报告 公司代码：688091 公司简称：上海谊众 上海谊众药业股份有限公司 2025 年半年度报告 1 / 153 上海谊众药业股份有限公司2025 年半年度报告 重要提示 一、 本公司董事会及董事、高级管理人员保证半年度报告内容的真实性、准确性、完整性，不 存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 重大风险提示 报告期内，公司不存在对生产经营构成实质性影响的重大风险。公司已在本报告中详述公司 在经营过程中可能面临的相关风险，详见本报告第三节"管理层讨论与分析"中"风险因素"的 相关内容。 三、 公司全体董事出席董事会会议。 四、 本半年度报告未经审计。 五、 公司负责人周劲松、主管会计工作负责人汤节节及会计机构负责人（会计主管人员）阮天 一声明：保证半年度报告中财务报告的真实、准确、完整。 六、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 报告期内，公司无利润分配或资本公积金转增股本的预案。 七、 是否存在公司治理特殊安排等重要事项 □适用 √不适用 八、 前瞻性陈述的风险声明 √适用 □不适用 本报告中所涉及的关于公司未 ...

Core Insights - Shanghai Yizhong (688091.SH) reported a revenue of 160 million yuan for the first half of 2025, representing a year-on-year growth of 31.48% [1] - The net profit attributable to shareholders reached 38 million yuan, an increase of 10.13% compared to the previous year [1] - The company's non-recurring net profit was 37.06 million yuan, reflecting a year-on-year growth of 11.74% [1] - Basic earnings per share stood at 0.18 yuan [1] Revenue Growth - The significant revenue growth of 31.48% was primarily driven by the inclusion of the core product, paclitaxel micelles, in the national medical insurance catalog [1] - Sales volume of paclitaxel micelles saw a remarkable increase of 487% compared to the same period last year [1]

国金证券股份有限公司 一、 募集资金基本情况 经中国证券监督管理委员会于 2021 年 8 月 3 日发布的《关于同意上海谊众 药业股份有限公司首次公开发行股票注册的批复》（证监许可[2021]2595 号）同 意，公司向社会公众公开发行人民币普通股（A 股）股票 2,645.00 万股，每股面 值 1 元，发行价格为每股人民币 38.10 元，募集资金总额为人民币 100,774.50 万 元，扣除发行费用 7,171.45 万元，募集资金净额为 93,603.05 万元。 截至 2021 年 9 月 3 日，公司本次募集资金净额 93,603.05 万元已全部到位， 并由容诚会计师事务所（特殊普通合伙）对公司募集资金的到位情况进行了审验， 并出具了容诚验字[2021]201Z0041 号《验资报告》，公司依照规定对上述募集资 金进行专户存储管理，并与保荐机构、募集资金专户监管银行签订了募集资金专 户存储监管协议。 二、募集资金使用情况 按照上海谊众《首次公开发行股票并在科创板上市招股说明书》披露的募集 资金投资项目及募集资金使用计划，以及公司根据实际募集资金的情况对募投项 目使用募集资金金额进行的调整，公 ...

Core Viewpoint - Shanghai Yizhong (688091.SH) reported significant growth in its core product, paclitaxel micelles, with sales increasing approximately 487% year-on-year, indicating strong market demand and operational performance [1] Financial Performance - The company achieved operating revenue of 160.31 million yuan, representing a year-on-year increase of 31.48% [1] - Net profit attributable to shareholders reached 38.00 million yuan, reflecting a year-on-year growth of 10.13% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 37.06 million yuan, which is an increase of 11.74% compared to the same period last year [1]

人民财讯8月7日电，上海谊众(688091)8月7日晚间披露2025年半年度报告，公司上半年实现营业收入1.6 亿元，同比增长31.48%；归母净利润3800.38万元，同比增长10.13%；基本每股收益0.18元。 ...

Group 1 - The core viewpoint of the article highlights that Shanghai Yizhong reported a revenue of 160 million yuan in the first half of 2025, representing a year-on-year growth of 31.48% [1] - The net profit for the same period was 38.0038 million yuan, showing a year-on-year increase of 10.13% [1] - The significant revenue growth is primarily attributed to the inclusion of the core product, paclitaxel micelles, in the national medical insurance catalog, which led to a remarkable sales increase of 487% compared to the same period last year [1]

Core Viewpoint - The total margin balance of the STAR Market reached 173.65 billion yuan on August 1, showing a slight increase compared to the previous trading day [1] Group 1: Margin Balance - The financing balance amounted to 173.03 billion yuan, increasing by 416 million yuan from the previous trading day [1] - The margin trading balance was 617 million yuan, which decreased by 17 million yuan [1] Group 2: Stock Performance - On August 1, 264 stocks in the STAR Market experienced net financing inflows, with 10 stocks having net inflows exceeding 50 million yuan [1] - Ruikeda topped the list with a net financing inflow of 243 million yuan, followed by Dongxin Co., Nine Company, Shanghai Yizhong, Haiguang Information, Zhongwei Company, and Suochen Technology with net inflows of 84.27 million yuan, 82.98 million yuan, 78.64 million yuan, 74.71 million yuan, 66.72 million yuan, and 61.01 million yuan respectively [1]

Market Overview - The main funds in the Shanghai and Shenzhen markets experienced a net outflow of 34.062 billion yuan, with the Sci-Tech Innovation Board seeing a net outflow of 4.184 billion yuan [1] - A total of 242 stocks saw net inflows, while 345 stocks experienced net outflows [1] Sci-Tech Innovation Board Performance - On the Sci-Tech Innovation Board, 341 stocks rose, with two stocks, Ruikeda and Shenlian Biological, hitting the daily limit, while 241 stocks declined [1] - The stocks with the highest net inflows included Gaoce Co., Ltd. with 107.17 million yuan, followed by Jinpan Technology and Shanghai Yizhong with 89.50 million yuan and 89.26 million yuan respectively [2] Continuous Fund Flow - There are 39 stocks that have seen continuous net inflows for more than three trading days, with Kexin Co., Ltd. leading at eight consecutive days of inflow [2] - Conversely, 194 stocks have experienced continuous net outflows, with ST Yifei leading at 15 consecutive days of outflow [2] Key Stocks with Fund Inflows - The top stocks by net inflow include: - Gaoce Co., Ltd. (107.17 million yuan, 16.58% inflow rate, 1.91% increase) [2] - Jinpan Technology (89.50 million yuan, 7.08% inflow rate, 6.89% increase) [2] - Shanghai Yizhong (89.26 million yuan, 9.54% inflow rate, 7.79% increase) [2] Key Stocks with Fund Outflows - The stocks with the highest net outflows include: - Dongxin Co., Ltd. (816 million yuan, 11.37% decrease) [1] - Hanwujing and Lankai Technology with net outflows of 411 million yuan and 391 million yuan respectively [1]